Thanks @Nasdaq for celebrating our recent partnership with @chugai_cc to develop novel therapies for age-related diseases. 🧬🧬

Read the news: shorturl.at/JZAck

Introducing the minds driving healthcare forward.

Our speakers represent the full spectrum of the healthcare landscape, from precision medicine and AI to policy, community health, and next-generation technologies, bringing the insights shaping the future of care to the 5th iddle East Healthcare Leaders Summit, held under the Patronage of H.E. Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and Coexistence, and presented by @PureHealthae , on September 22–23 at Emirates Palace Mandarin Oriental, Abu Dhabi.

Be in the room. Register now:
forbesmiddleeastevents.com/healthcare-lea…

@hacking_aging

Curious to learn more about Gero? ⬇️

Our mission is to eliminate the root causes of age-related diseases by designing drugs that treat aging as a system-level failure, not a fixed destiny.

💻 Discover how we’re making it happen: gero.ai

Menopause affects nearly every woman, yet there are zero drugs in development beyond symptom management. 📉

OVARIA, the joint effort between Gero and @athenabiorg, combats this by running genome-wide and rare-variant association studies to identify new therapeutic targets.

💻 Gero Co-founder and CEO, @fedichev, spoke more about where this initiative is headed with AthenaBIO: athenadao.substack.com/p/drug-discove…

We aim to identify mechanisms that influence the rate of aging.

Our mission at Gero is to develop drugs that restore resilience, delay disease, and double healthy human lifespan within a single generation.

💻 Learn more about our work in @LongevityTech: longevity.technology/news/gero-rais…

Aging is complex. 📊

At Gero, our work to extend functional lifespan is enabled by a physics-first approach.

📽️Our Co-founder and CEO, @fedichev, shared more about how our models work with @MHealthspan: youtu.be/NU8RAZhQhT4?si…

Unlike other longevity-focused biotechnology companies, our approach at Gero is centered on slowing the biological processes underlying aging. ✔️

Our models are designed to distinguish between reversible disease mechanisms, helping to identify therapeutic targets. 🧬

💻 Read more about our latest strides in citybiz: citybiz.co/article/861600…

Our recent funding round at Gero will support the preclinical development of our pipeline and expand our pharmaceutical partnerships. 🧬

Now, we can further develop our breakthrough medicines designed to slow aging, treat age-related diseases, and extend functional lifespan.

💻 Learn more about what’s next for Gero in @pulse2news: pulse2.com/gero-raises-17…

The @nebiusai Discovery Awards 2026 were a success. 🏆

We’re thrilled to share that Gero earned an Honorable Mention for our ProtoBind platform, a generative AI model for small-molecule design directly from protein sequence, placing among the top 10 projects in our category.

👏 Learn more about this honor: nebius.com/ai-discovery-a…

Learn more about ProtoBind: globenewswire.com/news-release/2…

The harsh truth. ⬇️

Despite improving health and lifestyle choices, people are not getting younger. 👀

Aging is a physics problem that molecular biology alone cannot answer, and that’s exactly what we’re working to solve at Gero.

📺 Our Co-founder and CEO, @fedichev, shared more about our mission with @MHealthspan: youtu.be/NU8RAZhQhT4?si…

We’re thrilled to announce that Eileen Brandenburger has joined Gero as our new Head of Intellectual Property and Licensing! 🧬

In her role at Gero, she’ll lead our commercial and technical IP legal work, drawing on her expertise in the field.

Welcome to the team, Eileen.

We’re accelerating at Gero from a discovery engine to a preclinical-stage drug developer. 👏

By reaching $34M in total funding, including a new $17M round to advance the preclinical pipeline in age-related diseases, we’re on track to pioneer a new class of medicines.

🧬 Learn more about our latest step in revolutionizing the aging process: businesswire.com/news/home/2026…